Loading...
OTCMTOMDF
Market cap1kUSD
Dec 20, Last price  
0.00USD
1D
0.00%
1Q
-99.00%
IPO
-100.00%
Name

Todos Medical Ltd

Chart & Performance

D1W1MN
OTCM:TOMDF chart
P/E
—
P/S
0.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
8m
-37.08%
000000005,207,00012,230,0007,695,000
Net income
-25m
L-66.64%
0-343,636-322,067-818,541-653,461-2,675,372-457,541-9,807,455-32,404,000-74,921,000-24,994,000
CFO
-3m
L-75.83%
00-317,548-614,654-469,389-904,410-1,056,296-1,276,239-2,558,000-11,224,000-2,713,000

Profile

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
URL
https://todosmedical.com
IPO date
Feb 21, 2017
Employees
7
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,695
-37.08%
12,230
134.88%
Cost of revenue
4,005
21,516
Unusual Expense (Income)
NOPBT
3,690
(9,286)
NOPBT Margin
47.95%
Operating Taxes
13
31,607
Tax Rate
0.35%
NOPAT
3,677
(40,893)
Net income
(24,994)
-66.64%
(74,921)
131.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
700
16,255
BB yield
-5.52%
-40.92%
Debt
Debt current
5,301
2,023
Long-term debt
33,047
29,870
Deferred revenue
46
Other long-term liabilities
226
323
Net debt
37,819
31,209
Cash flow
Cash from operating activities
(2,713)
(11,224)
CAPEX
(74)
(1,097)
Cash from investing activities
(1,807)
(4,706)
Cash from financing activities
4,365
15,184
FCF
10,103
(42,041)
Balance
Cash
34
189
Long term investments
495
495
Excess cash
144
72
Stockholders' equity
(110,708)
(87,682)
Invested Capital
114,392
95,337
ROIC
3.51%
ROCE
92.27%
EV
Common stock shares outstanding
1,425,643
679,575
Price
0.01
-84.77%
0.06
-22.07%
Market cap
12,688
-68.06%
39,721
104.35%
EV
51,129
70,930
EBITDA
4,440
(8,523)
EV/EBITDA
11.52
Interest
14,850
28,607
Interest/NOPBT
402.44%